- Home
- MUA vs NMRA Comparison
MUA vs NMRA Comparison
Compare MUA & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MUA | NMRA |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 424.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MUA | NMRA |
|---|---|---|
| Price | $10.85 | $2.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 92.6K | ★ 980.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.61 | $0.61 |
| 52 Week High | $11.43 | $11.57 |
Technical Indicators
Market Signals| Indicator | MUA | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 39.73 |
| Support Level | $10.71 | $2.05 |
| Resistance Level | $11.04 | $2.36 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 65.52 | 15.32 |
Price Performance
Historical ComparisonAbout MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.